Essential Partners’s Rocket Pharmaceuticals RCKT Stock Holding History

Essential Partners’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$5.6K	Sell	2,130 -1,514	-42%	-$5.25K	﹤0.01%	1454
2026 Q2	$12.5K	Sell	3,644 -9,897	-73%	-$32.9K	0.01%	1118
2026 Q1	$48.5K	Buy	13,541 +10,670	+372%	+$42.4K	0.02%	611
2025 Q4	$10.1K	Buy	2,871 +91	+3%	+$312	﹤0.01%	1169
2025 Q3	$9.06K	Buy	2,780 +865	+45%	+$2.72K	﹤0.01%	1198
2025 Q2	$4.69K	Buy	+1,915	New	+$9.7K	﹤0.01%	1072

Other funds holding RCKT

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

SMH

Sanders Morris Harris Houston, Texas $755M AUM 11.28% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Essential Partners's RCKT Position: Q3 2026 in Review

Essential Partners reduced its Rocket Pharmaceuticals (RCKT) stake by 42% in Q3 2026, selling an estimated $5.25K and leaving 2,130 shares worth $5.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1454.

Essential Partners first reported a position in RCKT in Q2 2025 and has held it in 6 quarters since. The position peaked at $48.5K in Q1 2026. 10 funds tracked by Wall St. Rank hold RCKT as of Q3 2026.

Essential Partners held 2,130 shares of Rocket Pharmaceuticals worth $5.6K as of Q3 2026.
Essential Partners sold 1,514 Rocket Pharmaceuticals shares in Q3 2026, an estimated $5.25K.
Rocket Pharmaceuticals made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #1454 holding.
Essential Partners first reported a position in Rocket Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
Essential Partners's Rocket Pharmaceuticals position peaked at $48.5K in Q1 2026.
10 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.